Clinical trials: Healthy Male
Healthy Subjects
Comparison of Pharmacokinetics of Infacort® Versus Immediate-release Hydrocortisone
This was a single centre, open-label, randomised, 5-way crossover study.
- Trial name
- NCT02777268
- Testing
- Infacort, Hydrocortisone
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Neurocrine UK Limited
Healthy Subjects
Clinical Study to Investigate the Effect of Macitentan on the Concentrations of Rosuvastatin in the Blood of Healthy Male Subjects
The aim of this Phase 1 trial is to study a potential drug-drug interaction between macitentan and rosuvastatin, a model substrate of various transporter proteins (e.g. in the gut).
- Trial name
- NCT03359291
- Testing
- Rosuvastatin, Macitentan
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Actelion
Healthy Volunteers
A Single Oral Dose Study to Evaluate Four Different Formulations of AZD9977 and the Effect of Food in Healthy Male Subjects
This study will evaluate pharmacokinetics (PK) of four different formulations with different release profiles of AZD9977 (PART A) in the fasted state, and one of the formulation will be selected for further development (Part B).
- Trial name
- NCT03450759
- Testing
- AZD9977 Oral suspension (reference), AZD9977 capsule, AZD9977 ER capsule (fastvrate)
- Where
- United Kingdom
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers, Polycystic Kidney, Autosomal Dominant
Effect of Venglustat in Patients With Renal Impairment
Primary Objective: To study the effect of mild, moderate and severe renal impairment on the pharmacokinetics (PK) of Venglustat following a single dose.
- Trial name
- NCT03687554
- Testing
- Venglustat GZ/SAR402671
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Genzyme, a Sanofi Company
Healthy
Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809
To investigate safety, tolerability, and pharmacokinetics of BI 425809 following single rising doses of BI 425809 in healthy male volunteers; To explore dose proportionality of BI 425809 as oral drinking solution; To investigate…
- Trial name
- NCT02068690
- Testing
- BI 425809 PfOS, BI 425809 tablet
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Kidney Stone, Healthy
Oxalate and Citrate in Humans - Response to Citrate
This is a single-center study that aims to learn more about how two compounds found in food, oxalate and citrate, interact in the body and may influence a person's chances of forming kidney stones.
- Trial name
- NCT06944223
- Testing
- Kidney stone formers, Control cohort
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Healthy
Effect of Steady State Meloxicam on Low Dose Aspirin Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females
The objective of this study was to investigate the influence of meloxicam on low dose aspirin induced inhibition of platelet aggregation and thromboxane B2, when meloxicam is given before aspirin.
- Trial name
- NCT02187562
- Testing
- Meloxicam, Aspirin
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Congenital Adrenal Hyperplasia, Exercise Capacity
Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH
Congenital Adrenal Hyperplesia (CAH) is a group of automosal recessive disorders that develop due to a deficiency of one of the five enyzmes necessary for cortisol synthesis in the adrenal cortex.
- Conditions
- Congenital Adrenal Hyperplasia, Exercise Capacity, Physical Activity, Quality of Life
- Trial name
- NCT06449456
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Healthy, Obesity
A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight
Part 1: To investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 3034701 in Japanese male and female participants with body mass index (BMI) ≥27.0 kg/m² or more following subcutaneous…
- Trial name
- NCT07693231
- Testing
- BI 3034701
- Where
- 3 sites in Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Male Volunteers to Test How the Test Medicine GLPG1972 is Taken up by the Body When Given by Mouth and Into the Vein as an Injection
The sponsor wants to investigate in this study how well the test medicine is taken up by the body when given orally (by mouth) as a tablet and solution, and as a solution for infusion (into a vein).
- Trial name
- NCT04136327
- Testing
- GLPG1972 film-coated tablets, [14C]-GLPG1972 solution for infusion, [14C]-GLPG1972 oral solution
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Healthy
A Study in Healthy Japanese Men to Test How Well Different Doses of BI 3006337 Are Tolerated
The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BI 3006337 in healthy male subjects following s.c.
- Trial name
- NCT06310005
- Testing
- BI 3006337
- Where
- Japan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteer, Muscular Dystrophies
Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers
This is a Phase 1 2-part, single-center, open-label study in healthy male volunteers. Part A will assess the absorption, metabolism, excretion, and pharmacokinetics of one oral dose of radiolabeled EDG-5506.
- Conditions
- Healthy Volunteer, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases
- Trial name
- NCT05730842
- Testing
- EDG-5506 Tablet, Radiolabeled EDG-5506 Suspension, Radiolabeled EDG-5506 Intravenous
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Edgewise Therapeutics, Inc.
Healthy Volunteers, Bioequivalence Study
Bioequivalence Study of Klaribact (Clarithromycin) 500 mg, Film Coated Tablet
This is An Open Label, Randomized, Single Dose, Two Way Cross over, Two Period, Two Treatment, Two Sequence Bioequivalence Study to compare the rate and extent of absorption of Klaribact FC Tablet (Clarithromycin 500 mg) with…
- Trial name
- BE (NCT05436769)
- Testing
- Klaribact 500 mg Clarithromycin Tablet, Klaricid 500 mg Clarithromycin Tablet
- Where
- Pakistan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Karachi
Healthy
A Study to Assess Mass Balance Recovery, Metabolite Profile and Identification of IV and Oral 14C-BC-3781
This is a single-centre, open-label, non-randomized, single dose study in healthy male subjects designed to assess mass balance recovery, metabolite profile and metabolite identification of radio-labeled BC-3781 administered via…
- Trial name
- NCT03131141
- Testing
- BC-3781
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Nabriva Therapeutics AG
Healthy Adult, Physical Condition
Isokinetic Strength and Anaerobic Capacity
This study aims to investigate differences in isokinetic knee extensor and flexor strength parameters among recreationally active young adult males classified into low, moderate, and high anaerobic power groups based on relative…
- Trial name
- ISAC (NCT07376551)
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Uludag University
Healthy
Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects
Primary Objective: Investigate the possible role of the CYP2C19 genotype in Adenosine diphosphate (ADP)-induced platelet aggregation after administration of a standard dose regimen of clopidogrel (300 mg loading dose followed by…
- Trial name
- NCT01123824
- Testing
- CLOPIDOGREL
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sanofi
Primary Hyperoxaluria
Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria
This is a double-blind, placebo-controlled, dose escalation trial of DCR-PHXC in Healthy Volunteers (HVs) and patients with Primary Hyperoxaluria (PH).
- Trial name
- NCT03392896
- Testing
- DCR-PHXC
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Healthy Volunteers
Trial on Single/Multiple Ascending Doses for Safety, PK and PD for CBP-0276 in Healthy Subjects
A double-blind, randomized, placebo-controlled, single and multiple ascending dose study with food effect to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CBP-0276.
- Trial name
- CBP276SADMAD (NCT07708831)
- Testing
- CBP-0276 Acetate
- Where
- 2 sites in Mexico
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Clarent Biopharma, Inc.
Clinical Pharmacology, Healthy Volunteer Study
A Phase 1 QT Study in Healthy Male Subjects
This is a single-center, randomized, double-blind crossover study with four treatments, four periods and four sequences to investigate the effects of orally administered pomalidomide on QT interval.
- Trial name
- QT/QTc (NCT01986894)
- Testing
- Pomalidomide, Moxifloxacin
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Celgene
Healthy
Pharmacokinetics, Safety, and Tolerability Study of the Autoinjector and Pre-filled Syringe of SB4 in Healthy Male Subjects
The purpose of this study is to compare the pharmacokinetics, safety, and tolerability of the autoinjector and pre-filled syringe of SB4 in healthy male subjects.
- Trial name
- NCT03193203
- Testing
- Etanercept
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Samsung Bioepis Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.